Efficient technique for screening drugs for activity against Trypanosoma cruzi using parasites expressing β-galactosidase

Antimicrobial Agents and Chemotherapy

Volumn 40, Issue 11, 1996, Pages 2592-2597

  Buckner, Frederick S ^a   Verlinde, Christophe L M J ^a   La Flamme, Anne C ^a   Van Voorhis, Wesley C ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 GUANIDINOBENZIMIDAZOLE; AMPHOTERICIN B; BENZNIDAZOLE; BETA GALACTOSIDASE; CARBENDAZIM; FLUCONAZOLE; NIFURTIMOX; PHENYLBIGUANIDE; POLYENE ANTIBIOTIC AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BLOOD TRANSFUSION; CELL STRAIN 3T3; CHAGAS DISEASE; DRUG DETERMINATION; DRUG SCREENING; ESCHERICHIA COLI; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRYPANOSOMA CRUZI;

EID: 0029861640     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.40.11.2592     Document Type: Article

References (28)

1. Ajioka, J., and J. Swindle. 1992. The calmodulin-ubiquitin associated genes of Trypanosoma cruzi: their identification and transcription. Mol. Biochem. Parasitol. 57:127-136.
2. Berens, R. L., J. J. Marr, F. Steele da Cruz, and D. J. Nelson. 1982. Effect of allopurinol on Trypanosoma cruzi: metabolism and biological activity in intracellular and bloodstream forms. Antimicrob. Agents Chemother. 22: 657-661.
3. Campos, R., U. Amato-Neto, A. A. Moreira, H. B. de-Souza, M. Okumura, P. L. Pinto, L. M. Braz, M. F. Silva, and L. Matsubara. 1992. Evaluation of the therapeutic activity of fluconazole in acute experimental infection caused by Trypanosoma cruzi. Rev. Hosp. Clin. Fac. Med. São Paulo 47:174-175.
4. Chiari, E., A. Braga de Oliveira, D. S. Raslan, A. A. L. Mesquita, and K. G. Tavares. 1991. Screening in vitro of natural products against blood forms of Trypanosoma cruzi. Trans. R. Soc. Trop. Med. Hyg. 85:372-374.
5. Chung, S., R. D. Gillespie, and J. Swindle. 1994. Analyzing expression of the calmodulin and ubiquitin-fusion genes of Trypanosoma cruzi using simultaneous, independent dual gene replacements. Mol. Biochem. Parasitol. 63: 95-107.
6. Cover, B., and W. E. Gutteridge. 1982. A primary screen for drugs to prevent transmission of Chagas's disease during blood transfusion. Trans. R. Soc. Trop. Med. Hyg. 76:633-635.
7. Croft, S. L., J. J. Walker, and W. E. Gutteridge. 1988. Screening of drugs for rapid activity against Trypanosoma cruzi trypomastigotes in vitro. Trop. Med. Parasitol. 39:145-148.
8. Cruz, F. S., J. J. Marr, and R. L. Berens. 1980. Prevention of transfusion-induced Chagas' disease by amphotericin B. Am. J. Trop. Med. Hyg. 29:761-765.
9. de Castro, S. L., M. C. F. R. Pinto, and A. V. Pinto. 1994. Screening of natural and synthetic drugs against Trypanosoma cruzi. 1. Establishing a structure/activity relationship. Microbios 78:83-90.
10. de Castro, S. L., M. N. Soeiro, K. O. Higashi, and M. N. Meirelles. 1993. Differential effects of amphotericin B on the three evolutive stages of Trypanosoma cruzi and on the host cell-parasite interaction. Braz. J. Med. Biol. Res. 26:1219-1229.
11. Goad, J. L., R. L. Berens, J. J. Marr, D. H. Beach, and G. G. Holz, Jr. 1989. The activity of ketaconazole and other azoles against Trypanosoma cruzi: biochemistry and chemotherapeutic action in vitro. Mol. Biochem. Parasitol. 32:179-190.
12. Grunberg, E., G. Beskid, R. Cleeland, W. F. DeLorenzo, E. Titsworth, H. J. Scholer, R. Richle, and Z. Brener. 1967. Antiprotozoan and antibacterial activity of 2-nitroimidazole derivatives, p. 513-519. Antimicrob. Agents Chemother. 1966.
13. Hammond, D. J., B. Cover, and W. E. Gutteridge. 1984. A novel series of chemical structures active in vitro against the trypomastigote form of Trypanosoma cruzi. Trans. R. Soc. Trop. Med. Hyg. 78:91-95.
14. Hammond, D. J., S. L. Croft, J. Hogg, and W. E. Gutteridge. 1986. A strategy for the prevention of the transmission of Chagas' disease during blood transfusion. Acta Trop. 43:367-378.
15. Hammond, D. J., J. Hogg, and W. E. Gutteridge. 1985. Trypanosoma cruzi: possible control of parasite transmission by blood transfusion using amphiphilic cationic drugs. Exp. Parasitol. 60:32-42.
16. Hariharan, S., J. Ajioka, and J. Swindle. 1993. Stable transformation of Trypanosoma cruzi: inactivation of the PUB12.5 polyubiquitin gene by targeted gene disruption. Mol. Biochem. Parasitol. 57:15-30.
17. Horvath, A. E., and C. H. Zierdt. 1974. The effect of amphotericin B on Trypanosoma cruzi in vitro and in vivo. J. Trop. Med. Hyg. 77:144-149.
18. LaFlamme, A. C., F. S. Buckner, J. Swindle, J. Ajioka, and W. C. Van Voorhis. 1996. Trypanosoma cruzi: expression of interleukin-2 utilizing both supercoiled plasmids and linear DNAs. Exp. Parasitol. 83:159-163.
19. Moock, T. E., D. R. Henry, A. G. Ozkabak, and M. Alamgir. 1994. Conformational searching in ISIS/3D databases. J. Chem. Inf. Comput. Sci. 34:184-189.
20. Polak, A., and R. Richle. 1978. Mode of action of the 2-nitroimidazole derivative benznidazole. Ann. Trop. Med. Parasitol. 72:45-54.
21. Seeber, F., and J. C. Boothroyd. 1996. Escherichia coli β-galactosidase as an in vitro and in vivo reporter enzyme and stable transfection marker in the intracellular protozoan parasite Toxoplasma gondii. Gene 169:39-45.
22. Tomich, C. S. C., P. S. Kaytes, M. K. Olsen, and H. Palel. 1988. Use of lacZ expression to monitor transcription. Plasmid 20:167-170.
23. Traub-Cseko, Y. M., and H. Momen. 1995. On Chagas disease and leishmaniasis. Parasitol. Today 11:315-317.
24. Van Voorhis, W. C., and H. Eisen. 1989. FL-160: a surface antigen of Trypanosoma cruzi that mimics mammalian nervous tissue. J. Exp. Med. 169:641-652.
25. Verlinde, C. M. L. J., M. Callens, S. Van Calenbergh, A. Van Aerschot, P. Herdewijn, V. Hannaert, P. A. M. Michels, F. R. Opperdoes, and W. G. J. Hol. 1994. Selective inhibition of trypanosomal glyceraldehyde-3-phosphate dehydrogenase by protein structure-based design: toward new drugs for the treatment of sleeping sickness. J. Med. Chem. 37:3605-3613.
26. Verlinde, C. M. L. J., H. Kim, B. E. Bernstein, C. S. Mande, and W. G. J. Hol. Anti-trypanosomal drug development based on structures of glycolytic enzymes. In P. Veerapandian (ed.), Structure based drug design, in press. Dekker, New York.
27. Wendel, S., and J. C. Pinto Dias. 1992. Transfusion transmitted Chagas disease, p. 103-133. In S. Wendel, Z. Brener, M. E. Carmago, and A. Rassi (ed.), Chagas disease (American trypanosomiasis): its impact on transfusion and clinical medicine. ISBT, São Paulo, Brazil.
28. World Health Organization. 1991. Control of Chagas' disease. WHO Tech. Rep. Ser. 811:1-93.